ACAD insider buying and SEC filings, explained
Acadia Pharmaceuticals Inc. · CIK 1070494
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$785K
Planned sales (10b5-1)
$2.7M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 30, 2026 | Planned (10b5-1) | Mark C. Schneyer (CFO) sold 3,321 shares at $20.88 ($69K), marked as a 10b5-1 plan trade. Holdings down 4% to 71,322 shares. | SEC filing Filed Oct 30, 2026, 8:20 PM ET |
| Aug 5–6, 2026 | Planned (10b5-1) | Mark C. Schneyer (CFO) sold 20,141 shares between Aug 5 and Aug 6 at about $29.16 ($587K), marked as a 10b5-1 plan trade. Holdings down 23% to 67,828 shares. | SEC filing Filed Aug 7, 2026 |
| Jul 30, 2026 | Planned (10b5-1) | Elizabeth H.Z. Thompson (EVP, Head of Research & Dev) sold 16,558 shares at about $26.13 ($433K), marked as a 10b5-1 plan trade. Holdings down 47% to 18,994 shares. | SEC filing Filed Jul 31, 2026 |
| Jun 26, 2026 | Planned (10b5-1) | James Kihara (Principal Accounting Officer) sold 11,421 shares at about $26.08 ($298K), marked as a 10b5-1 plan trade. Holdings down 47% to 13,088 shares. | SEC filing Filed Jun 29, 2026 |
| May 26, 2026 | Sale | James Kihara (Principal Accounting Officer) sold 5,401 shares at about $21.18 ($114K). Holdings down 18% to 24,509 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 27, 2026 |
| May 4, 2026 | Planned (10b5-1) | Mark C. Schneyer (CFO) sold 3,506 shares at about $21.79 ($76K), marked as a 10b5-1 plan trade. Holdings down 5% to 66,145 shares. | SEC filing Filed May 5, 2026 |
| May 4, 2026 | Planned (10b5-1) | James Kihara (Principal Accounting Officer) sold 1,332 shares at about $21.79 ($29K), marked as a 10b5-1 plan trade. Holdings down 4% to 29,129 shares. | SEC filing Filed May 5, 2026 |
| Apr 7, 2026 | Planned (10b5-1) | Mark C. Schneyer (CFO) sold 2,709 shares at $22.20 ($60K), marked as a 10b5-1 plan trade. Holdings down 4% to 62,836 shares. | SEC filing Filed Apr 7, 2026 |
| Apr 7, 2026 | Planned (10b5-1) | James Kihara (Principal Accounting Officer) sold 1,030 shares at about $22.20 ($23K), marked as a 10b5-1 plan trade. Holdings down 4% to 27,865 shares. | SEC filing Filed Apr 7, 2026 |
| Mar 25–26, 2026 | Planned (10b5-1) | Mark C. Schneyer (CFO) sold 7,385 shares between Mar 25 and Mar 26 at about $21.55 ($159K), marked as a 10b5-1 plan trade. Holdings down 11% to 60,269 shares. | SEC filing Filed Mar 26, 2026 |
| Mar 25, 2026 | Planned (10b5-1) | Elizabeth H.Z. Thompson (EVP, Head of Research & Dev) sold 3,435 shares at $21.47 ($74K), marked as a 10b5-1 plan trade. Holdings down 51% to 3,280 shares. | SEC filing Filed Mar 26, 2026 |
| Mar 25, 2026 | Planned (10b5-1) | Adams Catherine Owen (CEO and Director) sold 11,641 shares at $21.47 ($250K), marked as a 10b5-1 plan trade. Holdings down 44% to 14,803 shares. | SEC filing Filed Mar 26, 2026 |
| Mar 25–26, 2026 | Planned (10b5-1) | James Kihara (Principal Accounting Officer) sold 1,942 shares between Mar 25 and Mar 26 at about $21.57 ($42K), marked as a 10b5-1 plan trade. Holdings down 7% to 26,885 shares. | SEC filing Filed Mar 26, 2026 |
| Mar 25, 2026 | Planned (10b5-1) | Jennifer J Rhodes (EVP, Chief Legal Officer, Sec) sold 3,844 shares at $21.47 ($83K), marked as a 10b5-1 plan trade. Holdings down 25% to 11,280 shares. | SEC filing Filed Mar 26, 2026 |
| Feb 9, 2026 | Planned (10b5-1) | Jennifer J Rhodes (EVP, Chief Legal Officer, Sec) sold 6,950 shares at about $23.38 ($162K), marked as a 10b5-1 plan trade. Holdings down 48% to 7,609 shares. | SEC filing Filed Feb 10, 2026 |
| Nov 18, 2025 | Planned (10b5-1) | Mark C. Schneyer (CFO) sold 10,262 shares at about $23.69 ($243K), marked as a 10b5-1 plan trade. Holdings down 16% to 53,338 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 18, 2025 | Planned (10b5-1) | James Kihara (Principal Accounting Officer) sold 4,084 shares at about $23.69 ($97K), marked as a 10b5-1 plan trade. Holdings down 14% to 25,058 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 10, 2025 | Sale | James M Daly (Director) sold 30,000 shares at about $22.37 ($671K). Holdings down 88% to 4,041 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 12, 2025 |
29 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ACAD in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.